Top 10 Life Science VC (Venture Capital) Funds in Ireland in April 2025

Last updated: Apr 2025 A list of 10 VC (Venture Capital) funds that invest in Life science startups based in Ireland. We rank investors based on the number of investments they made in Life science companies from Ireland. We update this investor list every month.

Top 10 Life Science VC (Venture Capital) Funds in Ireland in April 2025

Investor	Life Science Ireland investments
Enterprise Ireland	6
AIB Seed Capital Fund	5
SOSV	3
Johnson & Johnson Innovation – JJDC	1
Development Capital	1
Ireland Strategic Investment Fund	1
Carbery Group	1
Western Development Commission	1
European Investment Bank	1
KBI Biopharma	1

Find investors that fund startups like yours. Automatically.

Our algorithm will find investors that invest in your industry, stage, and geography.

Investor list

Enterprise Ireland is the government agency responsible for the development and funding of the indigenous business sector. Their mission is to accelerate the development of companies to achieve strong positions in global markets resulting in increased national and regional prosperity. It was founded in 1998 and headquartered in Dublin, Ireland.

Investment focus

Software, Health Care, Information Technology
Funding Round, Seed, Series A
Ireland, United States, United Kingdom

Portfolio highlights

VRAI — First and foremost, they are a content creation company specialising in virtual reality production. They are visual storytellers embracing this new medium as a way of creating immersive, engaging content.Their pioneering methodology takes elements from our diverse background. We use techniques from narrative cinema, from visual effects, fromexhibition design, from gaming, from brand management and combine them in new exciting ways to help you tell your story.
Advise — Advise Freemium is a ground-breaking automated data analytics for CPG solution. Discover how Advise can assist your Revenue Growth Management.
LaNua Medical — At LaNua Medical it is our mission to develop disruptive image-guided technologies providing safe and effective endovascular solutions.

The AIB Seed Capital Fund was established in 2007 to provide venture capital for companies at the seed and early stages of development across a range of sectors throughout the Republic of Ireland. The Fund was established under the Enterprise Ireland Seed and Venture Capital Programme 2007-2012.The Fund has a total of â‚¬30m under managementwith AIB and Enterprise Ireland both committing â‚¬15m. It is managed by experienced managers with extensive expertise in making seed and early stage investments, adding value and facilitating business success.The Fund managers are empowered to make seed investments of up to approximately â‚¬500,000. Furthermore, the Fund has the capacity to make investments in later rounds to support the continued growth of investee companies.The Fund will be managed by Enterprise Equity Venture Capital and the Dublin Business Innovation Centre. This unique partnership brings together extensive regional and investment expertise.Enterprise Equity will evaluate and manage all investments outside the city and county of Dublin, as well as investments that require in excess of â‚¬250,000 from the fund within the city and county of Dublin.Dublin Business Innovation Centre (DBIC) will evaluate and manage all investments within the city and county of Dublin when the initial investment amount required from the Fund does not exceed â‚¬250,000.

Investment focus

Software, Health Care, Medical
Seed, Funding Round, Series A
Ireland, United States, Jersey

Portfolio highlights

NewsWhip — The only real-time media monitoring platform that predicts the stories and topics that will matter in the hours ahead.
Offr — Offr is the new way to buy and sell property, quickly and transparently.
Metabolomic Diagnostics — Metabolomic Diagnostics is a deep-tech company specialized in the development of novel biomarker based diagnostic solutions for complex diseases. The company has developed an effective pipeline to firstly identify diagnostic biomarker panels and then translate these panels into clinical assays ready for application in the clinical laboratory.Thispipeline combines the biomarker multiplexing capabilities of Mass Spectrometry, a powerful analytical technology, with the company’s own informatics and statistics solutions to deliver diagnostic innovation. This is reflected in Metabolomic Diagnostics’ strong and versatile IP portfolio of technical innovations and biomarkers.Our VisionMetabolomic Diagnostics’ primary vision is to develop a portfolio of diagnostic solutions which can determine, early in a woman’s pregnancy,her risk of developing major complications much later in her pregnancy and thus enabling personalized care, adapted to each woman’s individual needs. Pregnancy complications like preeclampsia, gestational diabetes, preterm birth, and in-uterine growth restriction, all have the potential to severely impact on the well-being of mother and child.The company’s innovative diagnostic solutions will assist clinicians in re-imagining how these conditions are managed: our novel risk assessment tools are specifically developed in conjunction with prenatal care providers to ensure they make a difference that really matters. This in turn will enable clinicians to improve pregnancy outcomes globally.Our solutions will empower pregnant women: accurate pregnancy risk information will allow a pregnant woman, in partnership with her care provider, to determine what prenatal care is best for her pregnancy.

SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.

Investment focus

Biotechnology, Health Care, Software
Seed, Convertible Note, Pre-Seed
United States, India, United Kingdom

Portfolio highlights

MixRift — MIXRIFT - game developers specialized in Mixed Reality
unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.

JJDC, Inc. is the strategic venture capital arm of Johnson & Johnson Innovation. Learn more about our equity investment strategy.

Investment focus

Health Care, Biotechnology, Medical
Series A, Series B, Series C
United States, Israel, France

Portfolio highlights

Citryll — Citryll is a private pharmaceutical company that develops pharmaceutical drugs used to treat autoimmune and other human diseases. The company offers formation, function, and clearance of NETs downstream of the protein citrullination pathway catalyzed by Peptidylarginine Deiminase (PAD) enzymes that enable doctors to help in the treatment of lupus,vasculitis, pulmonary fibrosis, rheumatoid arthritis and organ damage due to sepsis.Citryll was established in 2015 and is headquartered in Oss, The Netherlands.
TECLens — TECLens is creating a crosslinking technology that may accurately fix vision issues in healthy eyes as well as treat keratoconus. It provides patients with presbyopia with the ability to regain their ability to read at a distance, controls children's progressive myopia, corrects adult vision problems like hyperopia and low-order myopia, andmore.
Perceive Pharma — Perceive Pharma operates as a pharmaceutical company. Perceive Pharma develops innovative small molecule neuroprotective treatments.

At Development Capital, they are aware of the significant growth opportunities available to mid-sized companies and understand the management teams’ unique requirement for not only finance, but also for a funding partner who will bring experience, expertise and international reach to assist secure and maximise the business growth opportunity.Development Capital provides investee companies with a unique and unprecedented partnership approach which will maximise the growth opportunity in the most prompt and efficient manner. In addition to their experienced Investment Directors, their partners include:High profile and experienced Industry Experts who will provide direction and support to investee companies; andMajor Irish Corporates who have committed not only funding but also their international experience.

Investment focus

Manufacturing, Telecommunications, VoIP
Funding Round, Seed, Private Equity
Ireland, United States, United Kingdom

Portfolio highlights

IP Telecom — Ireland's most competitive SME & Enterprise VoIP provider. We are Ireland's leading VoIP Phone Systems Provider. Connect your business to the technology of today.
Nomadic Dairy — Nomadic Dairy is a growing, premium branded yogurt manufacturer. The company supplies multiple products across the UK and Republic of Ireland.
Spotlight Oral Care — Spotlight Oral Care aims to create the best oral health products, to educate and promote oral care, empowering people to engage with true customised preventative oral care.

The Ireland Strategic Investment Fund, managed and controlled by the National Treasury Management Agency (NTMA), is an €8.5 billion sovereign development fund with a unique mandate. We have a statutory mandate to invest on a commercial basis in a manner designed to support economic activity and employment in Ireland. With €8.5 billion availableto deploy, the Fund differs from other pools of capital in a number of key respects. It has a long investment time horizon and therefore can act as a permanent or patient source of long-term capital. It has flexibility up and down the capital structure and can therefore meet changing capital needs and gaps in the marketplace.The Fund will seek to invest in transactions where it can make a difference, where its characteristics can enable commercial investment transactions with positive economic impact and can make it an attractive “investor of choice” for company and project sponsors and advisors.We are a strategic investor with strong connections in both the public and private sectors. We are uniquely positioned to make connections and drive innovation across multiple industry players developing and delivering innovative opportunities that might otherwise go unrealised.

Investment focus

Software, Analytics, Biotechnology
Funding Round, Series C, Series D
Ireland, United States, Israel

Portfolio highlights

FIRE1 — FIRE1 and is based in Dublin, Ireland, will focus on developing novel therapeutic devices.
Aer Lingus — Aer Lingus is a national airline. They focus on aer lingus, business class, and aerClub.
Vectra AI — Vectra is the world leader in AI threat detection and response. The Cognito platform uses AI to detect attackers in real time and perform conclusive investigations.

Pioneering research and expertise in action. Through innovati drive new product innovation that creates value for our.

Investment focus

Life Science, Biotechnology, Marine Technology
Seed
Ireland

Portfolio highlights

Pure Ocean Algae — Pure Ocean Algae is a biotechnology company that integrates value chains from macro-algae and other marine resources. The company has over the winter of 2019/20 deployed its first trial lines of Palmaria palmata to sea, with initial results being extremely positive. It has also taken primary research in tank-based vegetative production andsucceeded in developing a pilot commercial plant that can produce commercial volumes of Palmaria palmata, at levels approaching 100% per week.

Supporting communities to grow, investing in businesses to scale and planning for the future of the western region.

Investment focus

Health Care, Medical Device, Biotechnology
Seed, Funding Round, Series A
Ireland, United States

Portfolio highlights

Ovagen — Ovagen is a biotechnology company that has developed the process of producing germ free (GF) chicken eggs and GF birds in commercial quantities for use primarily in the pharmaceutical industry. Ovagen can also provide a Contract Research Service and has extensive expertise in SPF poultry & rodent housing & husbandry, in specific poultry& rodent research technologies to GMP standards and in avian transgenics.
Peroptyx — Peroptyx is a platform that provides managed solutions for machine learning. At Peroptyx, they have assembled and pre-screened a qualified network of data evaluators across the globe. They strategically match ideal evaluators with each product to ensure authentic experiences through consistency and appropriate real-world contexts.
CitySwift — CitySwift is a data-driven scheduling and planning technology for urban bus networks. It uses artificial intelligence and machine learning to predict journey times and passenger demand, making routes more efficient. Schedulers can create optimized timetables that take into account traffic, events, and hundreds of other external factors, ensuringon-time performance and increased passenger satisfaction.CitySwift was established in 2016 and is operating in Galway, Ireland.

The European Investment Bank (EIB) offers lending, borrowing, and treasury services primarily within the European Union. It provides project loans for public and private sectors, loans to banks and intermediaries, structured finance products, guarantees, and securitization instruments for debts. Additionally, EIB offers equity and fund investmentproducts, including infrastructure and environmental funds, as well as venture capital funds. EIB also supports microfinance and risk-sharing finance for research and innovation and provides technical expertise for sustainable energy projects. Its services include infrastructure advisory, urban development support, guarantees for transport infrastructure, and funding for public-private partnerships and small- to medium-sized enterprises. The bank serves various sectors, including transportation, energy, health, education, and agriculture.

Investment focus

Biotechnology, Health Care, Energy
Debt Financing, Post-IPO Debt, Funding Round
Germany, France, The Netherlands

Portfolio highlights

Amadix — Amadix develops and commercializes breakthrough discoveries in cancer diagnosis with a clear commercial rationale, addressing unmet medical needs in oncology. After analytical validation and demonstration of clinical validity and utility through international multicentre studies, the products will be commercialized worldwide.The most advancedproduct developed by Amadix is Colofast, an innovative non-invasive screening signature for colorectal cancer (CRC) and advanced adenoma diagnosis in blood designed to solve a significant health priority: the high mortality rate due to colon cancer worldwide (around half of the diagnosed patients).Amadix team consist of industry veterans with robust expertise in the Oncology Diagnostic area. They are a top level management team with international experience in cancer diagnostics, the pharmaceutical industry, the biotechnology sector and intellectual property. Amadix also has independent board members with international profiles and many years of experience in oncology and diagnostics, who advise the management team on strategy, commercialization and business development in Europe and the US.
Greenlight Biosciences — Next Generation Crop Protection
Azienda Comprensoriale Acquedottistica — ACA Spa is an integrated water service company.

KBI Biopharma Inc. is a global contract development and manufacturing organization (CDMO / CMO) offering Cell Line Development, Process Analytical & Formulation Development, Clinical & Commercial Manufacturing, and more.